Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 17822:A Phase 1, Multi-center, Open-label, Dose finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC 94676 in Subjects with Metastatic Castration-resistant Prostate Cancer

99 years and younger
All genders
The primary purpose of this clinical research study is to test, for the first time in people, the safety (any good or bad effects) of the new experimental drug, CC-94676. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

UPCC 11123: A Phase Ib/III Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus Placebo plus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced

99 years and younger
All genders
This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i (palbociclib, ribociclib or abemaciclib) and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer. We would like to rely on WCG as the IRB of …
Learn More

UPCC 35419: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)

99 years and younger
All genders
This is a multicenter, interventional and observational study to understand factors affecting the likelihood of transplantation in patients without a human leukocyte antigen (HLA) matched family donor and to compare outcomes associated with pursuing an HLA-identical unrelated versus other alternative donor graft sources. Subjects' outcomes will be assessed using several …
Learn More

UPCC 13423: A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies

99 years and younger
All genders
This study will evaluate the long-term (up to 15 years) safety and efficacy of CRISPR CAR cellular therapy for hematological and solid malignancies. We would like to rely on WCG as the local IRB of record for this study.
Learn More

UPCC 36922: A Phase 1/2a open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and efficacy of mirdametinib in combination with BGB-3245 in patients with advanced solid tumors

99 years and younger
All genders
A Phase 1/2a dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with advanced metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy, or prior standard of care therapy …
Learn More

UPCC 12523: Real-world efficacy and safety, patterns of resistance and clinical progression among patients with Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion mutations: An ATOMIC Analysis

99 years and younger
All genders
This study is a retrospective and prospective medical record review of patients with NSCLC harboring EGFR ex20ins mutations treated at cancer centers participating in ATOMIC.
Learn More

UPCC 16423: Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid l

99 years and younger
All genders
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r. We would like to rely on WCG as the IRB of record for this study.
Learn More

UPCC 18923: A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

99 years and younger
All genders
The purpose of this study is to test the study drug, PC14586 alone and in combination with pembrolizumab in patients with an advanced solid tumor with a TP53 Y220C alteration who have gone through one or more anticancer therapies and are not responding. PC14586 will be tested at different doses …
Learn More

UPCC 13922 A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)

99 years and younger
All genders
Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints).
Learn More

UPCC 24922 First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section 5 (Trial Objectives) Please refer to Protocol 6.2.1 (Phase 1 Primary Endpoints) and Protocol Section 6.2.4 (Phase 2 Primary Endpoints) Please refer to Protocol 6.2.2 (Phase 1 Secondary Endpoint) and Protocol Section 6.2.5 (Phase 2 Secondary Endpoints)
Learn More
51 - 60 of 206